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As  legacy  toxicogenomics  databases  have  become  available,  improved  data  mining  approaches  are
now  key  to extracting  and visualizing  subtle  relationships  between  toxicants  and  gene  expression.  In
the  present  study,  a novel  “aggregating  bundles  of  clusters”  (ABC)  procedure  was  applied  to  separate
cholestatic  from  non-cholestatic  drugs  and  model  toxicants  in  the  Johnson  & Johnson  (Janssen)  rat  liver
toxicogenomics  database  [3].  Drug-induced  cholestasis  is  an  important  issue,  particularly  when  a  new
compound  enters  the  market  with  this  liability,  with  standard  preclinical  models  often  mispredicting  this
toxicity.  Three  well-characterized  cholestasis-responsive  genes  (Cyp7a1,  Mrp3  and  Bsep)  were  chosen
from  a previous  in-house  Janssen  gene  expression  signature;  these  three  genes  show  differing,  non-
redundant  responses  across  the  90+  paradigm  compounds  in our  database.  Using  the  ABC  procedure,
extraneous  contributions  were  minimized  in  comparisons  of  compound  gene  responses.  All  genes  were
assigned weights  proportional  to  their  correlations  with  Cyp7a1,  Mrp3  and  Bsep,  and a  resampling  tech-
nique  was  used  to derive  a stable  measure  of  compound  similarity.  The  compounds  that  were  known
to  be associated  with  rat cholestasis  generally  had  small  values  of  this  measure  relative  to  each  other
but also  had  large  values  of this  measure  relative  to non-cholestatic  compounds.  Visualization  of  the
data  with  the  ABC-derived  signature  showed  a  very  tight,  essentially  identically  behaving  cluster  of
robust  human  cholestatic  drugs  and  experimental  cholestatic  toxicants  (ethinyl  estradiol,  LPS,  ANIT  and
methylene  dianiline,  disulﬁram,  naltrexone,  methapyrilene,  phenacetin,  alpha-methyl  dopa,  ﬂutamide,
the  NSAIDs–—indomethacin,  ﬂurbiprofen,  diclofenac,  ﬂufenamic  acid,  sulindac,  and nimesulide,  buty-
lated  hydroxytoluene,  piperonyl  butoxide,  and  bromobenzene),  some  slightly  less  active  compounds
(3′-acetamidoﬂuorene,  amsacrine,  hydralazine,  tannic  acid),  some  drugs  that  behaved  very  differently,
and  were  distinct  from  both  non-cholestatic  and  cholestatic  drugs  (ketoconazole,  dipyridamole,  cypro-
heptadine  and  aniline),  and  many  postulated  human  cholestatic  drugs  that  in rat  showed  no  evidence
of  cholestasis  (chlorpromazine,  erythromycin,  niacin,  captopril,  dapsone,  rifampicin,  glibenclamide,  sim-
vastatin,  furosemide,  tamoxifen,  and  sulfamethoxazole).  Most  of these  latter  drugs  were  noted  previously
by other  groups  as  showing  cholestasis  only  in  humans.  The  results  of this  work  suggest  that  the  ABC
procedure  and  similar  statistical  approaches  can  be instrumental  in  combining  data  to  compare  toxi-
cants  across  toxicogenomics  databases,  extract  similarities  among  responses  and  reduce  unexplained
data  varation.
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. Introduction
Cholestasis, or the reduction of bile ﬂow, can progress to serious
epatotoxicity in patients and is a particular concern in evaluation
f novel drug candidates. Extrahepatic cholestasis occurs within the
ile duct, forming blockages via concentrated, precipitated drugs,
r by damage of the biliary epithelial cells, and loss of bile transport
nd ﬂow. Although a variety of drugs are concentrated in the bile,
rug-induced obstructive cholestasis is often readily observed pre-
linically, and can be avoided. Intrahepatic cholestasis associated
ith hepatotoxicity generally results from bile salt export pump
BSEP) inhibition, which if not adequately handled by accessory
athways such as MRP3, results in accumulation of detergent-
ike bile salts, that are toxic to hepatocytes. At high dose levels,
ovel drug candidates can bind to multiple hepatic transporters
nd trigger cholestatic signals. Therefore, screening for transporter
nhibition in membrane vesicles is a typical step in the drug dis-
overy and development process [21,22,25,33]. Identiﬁcation and
ranslational understanding of cholestatic responses in preclini-
al species is key step in the nonclinical safety assessment before
nitiating pharmaceutical clinical development.
The rat is a well-characterized model in which to study cholesta-
is, and is a principal species for preclinical toxicology studies.
here are some differences from human: bile salts are conjugated
y different enzymes (cholic acid and chenodeoxycholic acid are
redominantly conjugated with glycine in man  versus with taurine
n the rat), the molecular weight “ﬁlter” for drug biliary secretion
s generally lower than in humans (∼350 molecular weight in rat,
ersus ∼500 in humans), and the rat lacks a gall bladder [1,17]. This
atter difference is an experimental advantage in that there is more
onsistent bile ﬂow regulation in rats. Additionally, laboratory rats
at a well-deﬁned, carbohydrate-rich rodent chow and feed most
eavily during the dark cycle, more continually through the day
han most humans. These feeding habits contribute to less variation
n rat biliary transport and a continual and higher volume of bile
ow [10]. Despite numerous species differences when comparing
rug effects in rat to human, most transporter inhibition studies
how remarkable consistency; for example, no rat versus human
ifferences were observed in a large study of drug inhibition of
SEP transport [21].
A number of models of cholestasis in the rat are well stud-
ed and established: biliary ligation, which models bile duct
bstruction; ANIT, which damages/destroys biliary epithelium;
PS, which down-regulates much of the hepatic metabolism
ncluding most transporters; and glucuronidated ethinyl estradiol-
nduced cholestasis by inhibition of BSEP [2,7,11,20,23,34,36,39].
ll of these models have been characterized by gene expression on
icroarrays [7,11,34,39]. There is a misleading tendency to gener-
lize the speciﬁcs of each of these different models to all forms of
holestasis. For characterization of novel drug candidates, there is a
eed to capture as much of the invariant cholestasis gene response
s possible across a wide range of pharmaceutical structural classes.
At Janssen we have developed a predictive, 24 h treatment
at toxicogenomic database using approximately one hundred
on-proprietary treatments and four times as many proprietary
ompound treatments, the latter having supporting exposure, clin-
cal chemistry and histopathology data, often out to a month of
osing. We  have published predictive gene signatures for non-
enotoxic carcinogens [24,27] macrophage and PPAR receptor
ctivation [18] and particularly oxidative stress/reactive metabo-
ite responses for detecting idiosyncratic hepatotoxicants [14,15].
e previously developed a cholestasis gene expression signature
sing in-house proprietary compounds that induced cholestasis in
at studies (unpublished data). In the present study, we  have used
hree robust non-redundant genes (Cyp7a1, Mrp3 and Bsep) from
his previous rat signature which have been implicated in cholesta-ports 3 (2016) 252–261 253
sis [13,19,29,35]. Non-redundant genes differentially respond with
large variances to compounds across our database, therefore a
single one of these genes sufﬁces for relevant transcriptomics
information. Protein expression of MRP3 is up-regulated during
cholestasis and genetic defects in MRP3 have been linked with preg-
nancy or estrogen hormone-induced cholestasis [28]. Mutations of
the gene encoding the human bile salt export pump are implicated
in progressive familial intrahepatic cholestasis type 2 (PFIC2), and
inhibition of human and/or rat BSEP transporter constructs have
been demonstrated to be correlated to cholestatic potential [4].
CYP7A1 is an important participant in transcriptional regulation,
due to bile acid synthesis via nuclear hormone receptors and mod-
ulates cholestasis response via the classical pathway of bile enzyme
synthesis [12,26,31].
From this starting point of three genes, we  then applied the
“aggregating bundles of clusters” (ABC) statistical approach [3] to
develop a rat cholestasis gene expression signature that better
discriminates cholestatic from non-cholestatic compounds. Both
our unpublished proprietary signature and the present 100-gene
rat cholestasis signature of this work yield good separation of
compounds, and can discriminate many drugs known to cause
cholestasis in man.
2. Materials and methods
2.1. Animals
Male Sprague-Dawley rats, seven to eight weeks old, and
approximately 275 g body weight (Charles River Laboratories, Inc.)
were used for experiments. Animals were individually housed in
wire-bottom cages, on a 12 h/light/dark cycle, and fed Certiﬁed
Rodent Diet 5002 (LabDiet) ad libitum, with free access to water. On
the day prior to dosing, animals were randomized by weight and
allocated to groups (n = 3 rats/group). The route of administration
for each test article is denoted in Table 1. Oral gavage was the most
commonly utilized mode of administration as it is the typical route
for the majority of compounds (predominantly pharmaceuticals)
included in the training set. Animals were dosed in the morning
hours, with health checks performed at 1 h and 4 h after dosing, and
the end of the workday. Any animals deemed to be in poor health
status were evaluated by a veterinarian: in these experiments no
animals were prematurely terminated due to poor health.
Necropsy was  performed on fasted rats, 24 h following dosing.
Rats were killed by exsanguination, severing the vena cava under
CO2 analgesia, and liver sections (approximately 200 mg  of the right
medial lobe) were transfered to labeled cryo tubes and snap frozen
in liquid nitrogen.
The selected dose level was  the maximum tolerated dose, as elu-
cidated from the literature [18,24]. Compound selection rationale,
dose levels, route of exposure, group size, and experiment number
are documented within Johnson and Johnson publically-accessible
NIEHS-hosted database http://cebs.niehs.nih.gov.
In all instances, the animals were humanely handled and accord-
ing to institutional guidelines, in accordance with the IACUC and
NRC Guide for the Care and Use of Laboratory Animals.
2.2. Generation of microarray data
Total RNA was  extracted from liver samples using Qiagen
RNEasy Midi kits (Qiagen, Inc., Valencia, CA) as per kit instructions.
The amount of RNA in the samples was  determined spectrophoto-
metrically by absorbance ratio at 260 and 280 nm.  Quality of RNA
in the samples was  assessed using rRNA peaks determined by an
Agilent 2100 Bioanalyzer.
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Table 1
Figure abbreviations for cholestatic (red) and non-cholestatic (black) pharmaceuticals and model toxicants used in this study. Compounds were dosed via oral gavage (p.o.)
unless  otherwised noted (subcutaneous—s.c.; intraperitoneal—i.p.).
2-Acetamidofluorene Aceta Diclofenac Diclo Mifepristone Mifep
3-Acetamidophenol Aceta Dieldrin Dield Mycop henoli c Acid Mycop
Adrenocorti cotropin 
(s.c.) Adren Digoxin Digox Naltrexone Naltr
Aminoglutethimide 
(s.c.) Amino Dipyridamole Dipyr Niacin Niaci
Amiodarone Amiod Disulfiram Disul Nimesulide Nimes
Amsacrine (i.p) Amsac Doxorubicin Doxor Nizati dine Nizat
Aniline Anili ErythroMC Estolate Eryth Paraquat Paraq
α-
naphthylisothiocyanate ANIT Ethinyl Estradiol Ethin Perhexiline Perhe
Aspirin Aspir Etoposide Etopo Phenaceti n Phena
Atenolol Ateno Famotidine Famot Phenylephrine (i.p.) Pheny
Bromobenzene Bromo Flufenamic Acid Flufe Piperonyl butox ide Piper
Bromocryptine Bromo Fluoxetine Fluox Progesterone Proge
Buspiron e Buspi Flurbiprofen Flurb Puromycin Purom
Busulfan (i.p.) Busul Flutamide Fluta Raloxifene Ralox
Butylated 
hydroxy toluene Butyl Furosemide Furos Raniti dine Ranit
Cadmium Chloride Cadmi Gentamycin Genta Rifampin Rifam
Captopril Capto Glibenclamide Glibe Roteno ne Roten
Carbamazepine Carba Hydraz ine Hydrate Hydra Simvastatin Simva
Carmusti ne Carmu Ibup rofen Ibu pr Spironolactone (s.c.) Spiro
Chlorambucil Chlor Indo methacin (i.p.) Ind om Stanozolol (s.c.) Stano
Chlorpromaz ine Chlor Isoniazid Isoni Streptozocin (i.p.) Strep
Choleca lciferol (s.c.) Chole Isoproterenol (i.p.) Isopr Sulfamethoxazole Sulfa
Cisplati n Cispl Ketoconazole Ketoc Suli ndac Sulin
Cloza pine Cloza LPS (i.p.) LPS Tacrine Tacri
Cyclophosph amide Cyclo Mebendazole Meben Tamoxifen Tamox
Cyproterone Acetate Cypro Metformin Metfo Tannic Acid Tanni
Dacarbazine (i.p.) Dacar Methapyrilene Metha Testosterone (s.c.) Testo
Dantrolene Dantr Metho trexate Metho Tetracycline Tetra
Dapsone Dapso Methyldopa Methy Valproic Acid Valpr
li ne
p
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r
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aDexamethasone Dexam Methylenediani
Dichloroac etate Dichl Metoprolol
Reverse transcription of RNA with a T7 promoter oligo (dT)
rimer, followed by in vitro transcription using the RiboBeast 1-
ound Aminoallyl-aRNA Ampliﬁcation Kit was used for one round
f RNA ampliﬁcation (Epicentre, Madison, WI). Superscript II (Invit-
ogen, Carslbad, CA) was used as the reverse transcriptase, and the
neasy96 block was used for puriﬁcation (Qiagen, Valencia, CA) as
reviously described [24]. Puriﬁed biotin-labeled cRNA was  frag-
ented at 94 ◦C for 20 min  and added to Codelink hybridization
uffer A and B (GE Healthcare, Chandler, AZ). Each cRNA sam-
le was applied to two Codelink Rat Whole Genome microarrays
GE Healthcare) using the manufacturer’s protocol, and hybridized
t 37 ◦C overnight. Microarrays were washed, stained with an
lexa555-streptavidin conjugate (Invitrogen), and then scanned
t 532 nm with an Agilent G2565BA Microarray Scanner (Agi-Methy Verapamil Verap
Metop Vitamin A Vitam
lent Technologies, Palo Alto, CA). Fluorescence intensities for the
microarray features were determined using Codelink EXPv4.1 soft-
ware (GE Healthcare). Additional details regarding experimental
procedures may  be found in Ref. [18].
2.3. Preprocessing of microarray data
The data for this study was  part of a larger set of toxicoge-
nomic experiments which spanned several hybridization batches.
There were several vehicle controls run concurrently in each
hybridization batch to establish baseline gene expression lev-
els. The normalization procedure consisted of the following steps
within each hybridization batch: (i) spot winsorization on the log-
intensities to remove outliers; (b) quantile normalization to the
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edian of the vehicle controls in that batch; (c) mean summariza-
ion of the log-intensities for each gene of the technical replicates
or each RNA sample; (d) log ratios of the mean in (c) with the
edian of the vehicle control within the hybridization set. Details
f the winsorization and quantile normalization can be found in Ref.
3]. The dataset consists of log-ratios of the expression levels to the
edian vehicle control of the corresponding hybridization batch
s described above, for each sample, for the 35129 probesets on
he microarray chip. All analyses described below were conducted
n the probesets. Compounds that were known PPAR agonists and
acrophage activators (many of the acutely hepatototoxic com-
ounds) were omitted from analysis despite cholestatic properties,
ince their robust effects on gene expression interfered with subtle
ignatures, as noted previously [24,27]. LPS was added to the anal-
sis since it is an important cholestatic model compound in the
at.
.4. Public availability of microarray data
The data used in this study is from the non-proprietary Johnson
 Johnson (Janssen) toxicogenomics Codelink database, available in
ormalized ratio format in collaboration with Strand Life Sciences,
vt., Ltd., at the weblink: http://pubdata.strandls.com/ in the folder
jnj codelink data/” [30].
Raw data related to this project are also publically available in
he CEBS at the NIEHS website.
To access the CEBS website:
Go to http://cebs.niehs.nih.gov and select the “Open CEBS” option.
Select the “CEBS accession number” option under the “Search
Study” area.
Enter ‘004-00009-0000-000-3’ and select “Search.”
The folder “J&J Compounds of Known Toxicity” will appear. Open
folder by clicking on the arrow to view the studies in the database.
Details on each study may  be obtained by double clicking on that
ﬁle.
To access speciﬁc data by compound, organ, and Unigene ID,
select “J&J Codelink Data” in the “Workﬂows” area.
Data can be directly downloaded via the CEBS FTP site in two
ways. Go to http://cebs.niehs.nih.gov.
• Select “Download Data” option. All user submitted microarray
data and quantile normalized ﬁles are available at: ftp://157.98.
192.110/ntp-cebs/datatype/microarray/J&J/004-00009-0000-
000-3/ or can be found by selecting the options: Download
data > microarray > J&J > 004-00009-0000-000-3.
Alternatively, microarray data organized by study are available
at the link: ftp://157.98.192.110/ntp-cebs/FileList/004-00009-
0000-000-3/.
.5. Biostatistical analysis of the microarray data
A novel ABC-like procedure was applied [3]. The following three
teps were performed R times:
N compounds were selected at random with replacement. Any
repeats and/or replicates were discarded. Assume that this left
N* compounds (N* ≤ N). This is the “bag” of compounds for this
run.
An association score Ak was assigned to each gene k. Ak was taken
to be the maximum of the correlations between the kth gene and
each of the three focal genes across the N* samples; any gene that
was highly correlated to at least one of the three focal genes would
have a high association score. Under the premise that genes with
relatively large values of Ak were more likely to carry cholestasis
related information than genes with relatively small values ofports 3 (2016) 252–261 255
Ak, a weight wk was calculated for each gene k: wk = 1/(Rk +
√
G),
where Rk was the rank of Ak.
• √G genes were selected using weighted random sampling with-
out replacement with weights (wk). This small set of genes
included an overabundance of genes correlated with the three
focal genes. For only these N* compounds and G* genes, a cluster
analysis was  run using a standard clustering algorithm such as
Ward’s hierarchical clustering procedure to get a set of
√
N  base
clusters.
Once these steps were run R times, the results were collated.
Of the number of times that the ith and jth compounds were both
included in the same bag (in step (1) of the procedure), the propor-
tion Cij of times that they also fell into the same cluster (in step (3)
of the procedure) was determined.
Let Dij = 1 − Cij . A value of Dij close to zero indicated that com-
pounds i and j often clustered together in the base clusters, thereby
implying that they were relatively similar to each other. Alterna-
tively, a value of Dij close to 1 indicated that compounds i and
j rarely clustered together in the base clusters, thereby implying
that they were relatively dissimilar to one another. Thus Dij could
serve as a dissimilarity measure. Multidimensional scaling of (Dij)
was then used to generate a two-dimensional representation of the
similarities and dissimilarities of the compounds.
Following the ABC-like procedure, a boosting procedure incor-
porating an elastic net approach [16,41] was  applied and performed
1000 times, with frequencies calculated for all signature sets.
3. Results
Although an in-house proprietary cholestasis signature was
available our goal was to generate a robust gene expression sig-
nature using only non-proprietary drugs and compounds. Table 1
provides a list of cholestatic (red) and non-cholestatic (black) com-
pounds. Initially expression proﬁles of only three genes (Cyp7a1,
Mrp3 and Bsep), well characterized as cholestasis-responsive
genes, were examined. Their expression proﬁles, plotted in a
three-dimensional scatterplot, with known cholestatic compounds
highlighted in red, did not reveal a useful separation of the com-
pounds in any readily interpretable fashion (Fig. 1).
We next examined the simultaneous expression proﬁles of all
genes using several methods. One approach was to reduce the
dimensionality of the data using principal component analysis and
to then plot the ﬁrst two  components (Fig. 2). Another was to cal-
culate the dissimilarity between every pair of compounds using
either Euclidean distance (Fig. 3) or 1-correlation (Fig. 4) and to
then use multidimensional scaling to display the compounds on
a two-dimensional scatterplot [37]. This indicated fair separation
between groups, typical of many gene expression signatures, how-
ever many compounds in the two groups overlapped, with no
obvious basis for the way  cholestatic and non-cholestatic com-
pounds distributed in space. Clearly while it was insufﬁcient to
consider three key genes (Fig. 1), consideration of all genes was  also
unproductive (Figs. 2–4). Although such mild separations were con-
sidered acceptable in past studies [24], a better statistical analysis
method was  sought.
A novel approach based on the ABC (“aggregating bundles of
clusters”) technique was implemented [3]. The premise of this
method is that most of the genes do not contribute to the orga-
nization of the compounds but the analysis should tilt towards the
genes that do. Because the three selected “focal” non-redundant
genes Cyp7a1, Mrp3 and Bsep are implicated with cholestasis, other
gene responses could be ranked in importance by how much they
correlated to responses of these three genes. Application of the
ABC procedure yielded a display of the compounds that was  inter-
256 Y. Cherkas et al. / Toxicology Reports 3 (2016) 252–261
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Fig. 1. mRNA expression proﬁles of 3 genes (Cyp7a1, Mrp3 and Bsep) to cholestatic (red) and non-cholestatic (black) training set pharmaceuticals and model toxicants in
male  rat liver. Note that no clear separation was observed between classes.
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sig. 2. Principal component analysis of training set (plot of ﬁrst two  components). Th
 two-dimensional space reﬂecting the similarity of one compound to another.
retable in the context of cholestasis. Use of Dij as a dissimilarity
easure allowed for generation of a two-dimensional representa-
ion of similar and dissimilar compounds (Fig. 5). Compounds that
re similar to each other according to (Dij) are oriented close to one
nother while compounds that are dissimilar according to (Dij) are
paced further apart. Many of the best-characterized cholestaticlied methods generate a composite representative point with arbitrary units within
compounds (depicted in red) fell into a tight cluster on the lower
right-hand side of Fig. 5, and their gene responses after selection
were almost identical. An expanded view of this cholestatic cluster
is provided in Fig. 6. A few compounds with weaker responses, or
those that act via a different mechanism, displayed as a “bridge” in
this plot between the tight cluster of known cholestatic (red) com-
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Fig. 3. Two-dimensional scatterplot of training set using multidimensional scaling to illustrate dissimilarity between every pair of pharmaceuticals and model toxicants
based  on Euclidean distance. The applied methods generate a composite representative point with arbitrary units within a two-dimensional space reﬂecting the similarity
of  one compound to another.
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Fig. 4. Two-dimensional scatterplot of training set using multidimensional scaling to illustrate dissimilarity between every pair of pharmaceuticals and model toxicants
based  on 1-correlation. The applied methods generate a composite representative point with arbitrary units within a two-dimensional space reﬂecting the similarity of one
compound to another.
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Fig. 5. Two-dimensional projection of the similarities and dissimilarities of training set pharmaceuticals and model toxicants based on multi-dimensional scaling following
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Cholestatic potential of compounds on the lower right
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ia literature references. From this exercise, a ten-compound
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rointestinally toxic NSAIDs) and four-compound non-cholestatic
able 2
BC technique-derived prediction set of rat cholestatic and non-cholestatic phar-
aceuticals and model toxicants. Note the selected non-cholestatic compounds in
at  are all cholestatic in human patients.
Cholestatic compounds from
the right arm
Non-cholestatic compounds
from the left arm
Ethinyl Estradiol ErythroMC Estolate
Methylenedianiline Rifampin
ANIT Captopril
Disulﬁram Niacin
Piperonyl butoxide
Methapyrilene
Ketoconazole
Bromobenzene
Flutamide
Nimesulidetic compunds are noted in red. The applied statistical methods generate a composite
ilarity of one compound to another. A strong cholestatic (red) cluster can be noted
(non-cholestatic in rat, but cholestatic in human) compound train-
ing set (Table 2) was  used to derive an improved gene expression
signature for rat-speciﬁc cholestasis. We  applied a boosting pro-
cedure and elastic net methodology to select a signature set of
Codelink IDs [16,41]. The top set of 100 genes derived using an
arbitrary cutoff with highest frequencies (i.e., those with highest
statistical signiﬁcance) is recorded as our ﬁnal rat cholestasis sig-
nature and presented in Table 3.
Using the ABC approach, our results indicate that separation
of paradigm human cholestasis compounds into cholestatic/non-
cholestatic classes using rat experimental data gives as good or
better separation than that observed with our proprietary Johnson
& Johnson/Janssen compound-derived signature.
4. Discussion
In the present study the ABC statistical approach [3] was used
with three non-redundant cholestasis indicator genes, Cyp7a1,
Mrp3 and Bsep, to separate and visualize human cholestatic and
non-cholestatic compounds in the rat. Although these three genes
are well known to be regulated by the nuclear bile acid recep-
tor (FXR), their different responses across the drugs tested (their
non-redundant responses) suggest more complicated regulation in
rats, consistent with integrated bile salt, cholesterol, sterols and
other hepatic lipid metabolism pathways and the host of tran-
scription factors involved (such as LXR, SREBP, PPAR, PXR, CAR
and others, in addition to FXR and SHP; reviewed by Karagianni
and Talianidis [9]. These three starting genes are recognized to
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et  pharmaceuticals and model toxicants based on multi-dimensional scaling follow
epresentative point with arbitrary units within a two-dimensional space reﬂecting
e important in cholestasis, and were important in our previous
n-house cholestasis signature based on multiple doses of pro-
rietary compounds and histopathological evidence of cholestasis
Alex Nie, unpublished data). The separation by the ABC approach
f paradigm human cholestasis compounds into cholestatic/non-
holestatic compounds in the rat was as good or better than
bserved with the proprietary Johnson & Johnson/Janssen com-
ound derived signature. The ABC approach [3] was  used to
tatistically weigh additional genes according to their similar-
ty/dissimilarity to the three pivotal cholestasis genes and to derive
redictions for potential cholestatic propensities of our paradigm
ompounds. The most robust cholestatic and non-cholestatic com-
ounds in rat (all cholestatic in human) derived from this approach
ere used as a training set, along with a boosting procedure/elastic
et approach [41], to select a broad 100-gene signature set associ-
ted with rat-speciﬁc cholestasis.
The chief advantage of the ABC approach is that it allows tight
lustering of similar toxicants of interest (in this case rat cholestatic
ompounds) and displays the compounds along a continuum. Thus
he most active rat cholestatic compounds essentially behaved
dentically by gene expression: cholestatic model compounds ANIT,
PS, and ethinyl estradiol, many high dose NSAIDs which can cause
ut bleeding and endotoxin entry (phenacetin, ﬂurbiprofen, sulin-
ac, ﬂufenamic acid, nimesulide, indomethacin, diclofenac, and
buprofen [2,18], ﬂutamide, disulﬁram, methapyrilene, and the tool
ompounds piperonyl butoxide, bromobenzene, butylated hydrox-
toluene, and methylene dianiline clustered together). Naltrexone,
-acetamidoﬂourene, amsacrine, hydrazine and tannic acid were
lightly outside of the tight cholestatic cluster, and dipyridamole,
etoconazole and cyproterone acetate were further removed from
he cluster, showing different gene expression although quite dis-
ant from the non-cholestatic compounds.g. 1. Two-dimensional projection of the similarities and dissimilarities of training
he ABC clustering procedure. The applied statistical methods generate a composite
imilarity of one compound to another.
Aniline was the only known rat cholestatic compound that fell
in the “bridging” area between the cholestatic and non-cholestatic
compounds. Carbamazepine, clozapine and dieldrin also fell within
this bridging area, suggesting pronounced differences in gene
expression but also shared features with cholestatic compounds.
Erythromycin, glibenclamide, chlorpromazine, simvastatin, sul-
famethoxazole, and tamoxifen (all known cholestatic drugs in
human) were the closest of the non-cholestatic cluster to the
cholestatic compounds, but clearly non-cholestatic in the rat, at
least with acute dosing at high dose.
A number of pharmaceuticals that cause cholestasis in humans
do not appear to induce cholestasis in rats: chlorpromazine and
erythromycin-induced cholestasis appears to be human-speciﬁc
[5,8]. Other human cholestatic compounds such as furosemide,
rifampicin, niacin, captopril and dapsone showed no cholestatic
gene expression response in the rat which may reﬂects species
differences in cholestatic mechanisms such as binding and acti-
vation/inactivation of PXR, FXR, LXR and bile salt transporters [40].
Rifampin and glibenclamide reportedly block both rat BSEP and
human BSEP transport in vitro and produce cholestasis in patients
[25,33] but the rat appears to be much better at processing these
compounds and many other human cholestasis-inducing drugs [8].
Species differences in drug effects on metabolic regulatory path-
ways, drug-induced changes in bile salt solubility, interference with
clearance of other endogenous substrates (particularly steroid hor-
mones and bilirubin), and precipitation of compound in the bile
ducts, septicemia and localized inﬂammation, such as pancreati-
tis, and idiosyncratic/hypersensitivity and inﬂammation may  also
modulate cholestasis differently in man  versus the rat [38].
The regulation of the three cholestasis indicator genes Cyp7a1,
Bsep and Mrp3 used as the starting point for the ABC approach, and
the responses of these three genes across Janssen toxicogenomics
database compounds is different enough that several components
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Table 3
Rat speciﬁc cholestasis gene signature. The top 100 genes associated with rat
cholestasis, as derived by a boosting procedure with the elastic net approach. Genes
were selected by comparing compounds (all known cholestatic in patients) from
the  two training sets in Table 2.
Codelink Accession # Rat gene
GE1266870 BE115850 Gstcd
GE20245 NM 013215 Akr7a3
GE1298481 BM391646 Nars
GE21882 NM 031588 Nrg1
GE14709 AI230228 Psat1
GE1147805 CB578405 Zfp57
GE12632 AI704698 Tubb2c
GE16026 AW252110 Rexo2
GE1130267 BI296275 Mmd2
GE20928 NM 031828 Kcnma1
GE16596 AW915559 Pprc1
GE20102 NM 012991 Npap60
GE1206415 BI297088 Golt1b
GE15377 BI296275 Mmd2
GE15995 AW251324 Mthfd2-201
GE18028 BI273851 Hmgn1
GE1287407 BI282107 Pbdc1
GE1262741 BE110134 Similar to ATPase inhibitory factor 1
GE1259381 NM 138515 Cyp2d4v1
GE19894 NM 012674 Spink1
GE1173529 CA507720 Pgs1
GE16306 BQ206238 Ankhd1
GE1168184 NM 031318 Tctex1
GE13574 NM 053800 Txn1
GE1185733 BF552430 NosipGE1116501 BF565830
GE17633 BE110630 Fam98a
GE19200 BF550623 Cad
GE1128152 AF507943 GTPase Ran
GE1150923 BF398625 Yars
GE17038 H33863 Mrps27
GE1106781 BU760106 Tubb6
GE20964 NM 133539 Mrpl17
GE1287274 BF405056
GE1249888 BG380189 Map3k6
GE16626 BI302502 Fkbp11
GE1167706 NM 173102 Tubb5
GE1261576 BF416050
GE20940 NM 024390 Hpgd
GE18776 BF406522 Cdr2
GE17115 BE096047 Ran
GE1174448 BC062045 similar to lipase, member H
GE1181134 BM389611
GE19529 NM 134449 Prkcdbp
GE1101245 BF401159
GE15329 AI412180 Gsr
GE1170908 BE096969 Slc35e3
GE1195574 BG373486 Lsm4
GE20274 NM 017014 Gstm1
GE14242 BI291621 Coq6
GE1305121 AI235475 EST232037
GE12903 AA946350 Gnai1
GE1206195 BI274696 similar to Fam48a protein
GE19392 BG374448 TLOAEA57YJ04
GE1166787 BM391708
GE1291343 BQ202678 Xpo1
GE1219528 BF562712 Trmt10a
GE1135723 BM384823 Ppp1r3b
GE1237072 BQ202004 Gstm4
GE1277644 NM 031039 Gpt1
GE1236134 AW433632
GE22230 NM 053962 Sds
GE17670 BE113943 Tigar
GE1216317 BU759545 Trmt10a
GE1210818 NM 024148 Apex1
GE1125325 X78847 GstYc2
GE1262042 BI296358 Apmap
GE1100230 NM 138831 Slc16a10
GE12644 NM 175707 Ppil3
GE1297200 BF412090 Xkr8
GE1168155 BF288225 EST452816
GE17771 BE113165 Nek6
GE1205310 NM 133558 Cml1
GE22027 NM 053902 Kynu
Table 3 (Continued)
Codelink Accession # Rat gene
GE1197342 BQ194442 Krt23
GE15769 AA956532
GE14364 BG379780 Mcee
GE20988 NM 031051 Mif
GE1158473 BF521726 Srxn1
GE16476 BM388044
GE16012 H35647 Tnfrsf12a
GE18057 BF281848 Mthfd1l
GE1284234 AI169152 Mafb
GE1130388 AI137440
GE1167776 BF420077
GE16853 AW918024 Nif3l1
GE1119096 CA505586
GE1274350 BF388173 Ptprd
GE1201399 BF415461
GE15155 AI409108 Nup205 predicted
GE13570 NM 053439 Ran
GE15126 AI408727 Lurap1l
GE1296800 NM 184048 Taf9
GE16570 AW915407 EST346711
GE12527 BM384489 Hmgn3
GE1228263 BE098757
GE20373 NM 017147 Cﬂ1
GE1236758 NM 198771 Fam3c
GE19575 NM 053962 Sds
GE1210173 BF394858
of the rat cholestatic response are captured in our analysis. The
approach allows for improved characterization of cholestasis in
the rat than would be obtained using Cyp7a1 and other redundant,
identically regulated genes, such as Cyp8b1.
Importantly, the 100 genes comprising our derived rat cholesta-
sis signature would not have been obvious from most biochemical
pathway analyses. There were, however, several duplicate genes
with different accession numbers that were selected by the
algorithm (monocyte to macrophage differentiation associated,
Mmd2, tRNA methyltransferase 10a, Trmt10a, serine dehy-
dratase, Sds, glutathione transferases, Ran, high mobility group
nucleosome-binding proteins, Hmgns, and Methylenetetrahydro-
folate dehydrogenases, Mthfd), conﬁrming the gene selections.
Other transporters selected were for aromatic amino acids and
nucleotide sugars, and another Cyp selected, Cyp2d4, is well known
for 21-hydroxylation of steroid hormones rather than of bile salts or
cholesterol. The robustness of the three starting genes and selection
against strongly redundant responses means there are a limited
number of tightly linked and/or well-known cholestatic signature
genes.
In terms of in vivo study design, our experimental protocol was
designed for tissue collection at an optimal time point for detection
of robust gene expression changes. The non-proprietary paradigm
compounds used in this work were generally administered as single
dose, with animals necropsied 24 h later. Histopathology was  not
performed, as these compounds were typically well-characterized
for their cholestatic potential in rat and human. Additionally, this
acute treatment regimen was  not expected to induce clinical mani-
festation of cholestasis after such a short dosing period. Exploration
of dose-response and identiﬁcation of additional cholestatic agents
with multiple or chronic dosing regimens was not within the scope
of this study: such investigations may  yield additional insight and
improved predictivity.
While other microarray studies of cholestasis exist for the rat,
they have generally employed a single cholestatic agent. Such sig-
natures are appropriate for the individual particular cholestatic
model studied but may  be more limited when applied to the
variety of structural classes encountered in drug discovery and
development. Comparison to ethinyl estradiol EE-treatment (24 h
sampling time) showed minimal overlap with our >80 named
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